HPV driven cancers, including HPV+ HNSCC, are characterized by defects in the DDR pathway, making them potentially susceptible to WEE1 inhibition. HPV+ cancers are those where the underlying cause is ...
A patient with HPV-positive head and neck squamous cell carcinoma was dosed in a phase 1 clinical trial evaluating APR-1051.
Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...
Harry H. Yoon, MD, MHS, discusses tislelizumab and platinum-containing chemotherapy in unresectable or metastatic esophageal ...
"FDA approval of TEVIMBRA for the first-line treatment of advanced esophageal squamous cell carcinoma marks a significant step forward in tackling the unmet needs in this challenging disease area.
Trisha Wise-Draper, MD, PhD, discusses anticipated data on head and neck cancers and their potential impact on the field.
“FDA approval of Tevimbra for the first-line treatment of advanced esophageal squamous cell carcinoma marks a significant step forward in tackling the unmet needs in this challenging disease area. We ...
The FDA has approved Tevimbra with chemotherapy for the first-line treatment of unresectable or metastatic ESCC whose tumors express PD-L1.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback